Excreted Unchanged %
55-60
Half-Life (Normalesrd) Hours
3/No data
Plasma Protein Binding %
15-25
Volume Of Distribution L/Kg
0.9-1.9
Dose For Normal Renal Function
2.5-5 mg tid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
50% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [D]
References
Borgströ m L, Liu CX, Walhagen A. Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline. Chirality. 1989; 1: 174-7. [PMID: 2642046] / Borgströ m L, Nyberg L, Jö nsson S, Lindberg C, Paulson J. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br J Clin Pharmacol. 1989; 27: 49-56. [PMID: 2706188]
Toxicity Notes
Large first dose effect. Avoid parenteral doses in ESRD. Oral doses unchanged.